Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Revolution Medicines stole the day's biggest headline. An experimental pill showed meaningful results against pancreatic cancer — one of the deadliest tumour types. The AP story ranks as the highest-impact news of the morning. Options traders had already been positioning ahead of the catalyst. Short interest in RVMD sits at elevated levels, making this a high-stakes moment for bears.
A packed calendar kicks off today. Ulta Beauty reports Monday after the bell. Dollar General and Macy's follow Tuesday. prints Wednesday — and analysts are already cutting targets into the number. Thursday brings and . The consumer and defence-adjacent names dominate the slate.
OKLO is the week's most contested setup. Short interest jumped 21% in seven days to 23.5% of free float. Borrow availability is just 9.8% of SI. Squeeze risk is real with earnings due June 3. Meanwhile, Rubrik is seeing the opposite — options bulls have taken full control ahead of its own June 3 print. SAIC call buying hit a year-low put/call ratio, signalling strong bullish conviction from options traders.
European stocks slid broadly, but the defence sector rallied after Ukraine ratified a $105 billion EU loan deal. Separately, Dulux maker AkzoNobel surged after rejecting a $14.5 billion takeover bid. Oil stayed below $100 despite Chevron's CEO warning of a summer supply squeeze linked to the Strait of Hormuz blockade.
Three of the week's biggest insider filings stand out. Twilio saw a $184 million board-level sale. The Walton family offloaded over $250 million in Walmart stock. Ralph Lauren filed a $100 million sale in RL. Analysts, however, remained bullish — lifting targets sharply on Dell and F5 on AI infrastructure tailwinds.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
